Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 18/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8186567 | 0.95 | GNRHR (0.35) | GNRHREDNRBKMT2AKCNH2 | |
| SCHEMBL6704311 | 0.94 | GNRHR (0.36) | GNRHREDNRBKMT2AKCNH2 | |
| SCHEMBL7593195 | 0.93 | GNRHR (0.37) | GNRHREDNRBKMT2AKCNH2 | |
| SCHEMBL7593477 | 0.92 | GNRHR (0.36) | GNRHREDNRBKMT2AKCNH2 | |
| SCHEMBL7592385 | 0.92 | GNRHR (0.35) | GNRHREDNRBKMT2AKCNH2 | |
| SCHEMBL7592033 | 0.92 | GNRHR (0.37) | GNRHREDNRBKMT2AKCNH2 | |
| SCHEMBL8193067 | 0.91 | GNRHR (0.36) | GNRHREDNRBKMT2AKCNH2 | |
| SCHEMBL7598751 | 0.88 | GNRHR (0.36) | GNRHREDNRBKMT2AKCNH2 | |
| SCHEMBL7592912 | 0.87 | GNRHR (0.37) | GNRHREDNRBKMT2AKCNH2 | |
| SCHEMBL7594085 | 0.87 | GNRHR (0.36) | GNRHREDNRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0846119-B1 | THIENOPYRIMIDINE DERIVATIVES, THEIR PRODUCTION AND USE AS ENDOTHELIN ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-11-13 | — | — | EP | claimed |
| US-6140325-A | HAS ENDOTHELIN ANTAGONISTIC ACTION; FOR TREATING LIVER HYPOFUNCTION, ACUTE RENAL INSUFFICIENCY, CARDIAC INFARCTION OR LIVER INSUFFICIENCY, VASOCONSTRICTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-31 | — | — | US | claimed |
| EP-0846119-A1 | THIENOPYRIMIDINE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1998-06-10 | — | — | EP | claimed |
| WO-1997007119-A1 | THIENOPYRIMIDINE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-02-27 | — | — | WO | claimed |
| US-10828368-B2 | Therapeutic treatments using centhaquin | MIDWESTERN UNIVERSITY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | disclosed |
| EP-2424530-B1 | METHOD AND COMPOSITION FOR TREATING DIABETIC KETOACIDOSIS | UNIV MIDWESTERN (US) | 2015-12-16 | — | — | EP | disclosed |
| US-8980222-B2 | Diagnostic use of endothelin ETB receptor agonists and ETA receptor antagonists in tumor imaging | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980222-B2 | Diagnostic use of endothelin ETB receptor agonists and ETA receptor antagonists in tumor imaging | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-08-29 | — | — | US | disclosed |
| US-8410148-B2 | Method and composition for potentiating an opiate analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-04-02 | — | — | US | disclosed |
| US-20080260634-A1 | Diagnostic Use of Endothelin Etb Receptor Agonists and Eta Receptor Antagonists in Tumor Imaging | DONEHEW FUND LIMITED PARTNERSHIP | 2008-10-23 | — | — | US | disclosed |
| US-20080260634-A1 | Diagnostic Use of Endothelin Etb Receptor Agonists and Eta Receptor Antagonists in Tumor Imaging | DONEHEW FUND LIMITED PARTNERSHIP | 2008-10-23 | — | — | US | disclosed |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | UNIVERSITY OF ILLINOIS CHICAGO (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | UNIVERSITY OF ILLINOIS CHICAGO (US) | 2008-08-28 | — | — | US | disclosed |
| US-7351692-B2 | Method and composition for potentiating the antipyretic action of a nonopioid analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351692-B2 | Method and composition for potentiating the antipyretic action of a nonopioid analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-04-01 | — | — | US | disclosed |
| EP-0846119-B1 | THIENOPYRIMIDINE DERIVATIVES, THEIR PRODUCTION AND USE AS ENDOTHELIN ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-11-13 | — | — | EP | disclosed |
| US-6140325-A | HAS ENDOTHELIN ANTAGONISTIC ACTION; FOR TREATING LIVER HYPOFUNCTION, ACUTE RENAL INSUFFICIENCY, CARDIAC INFARCTION OR LIVER INSUFFICIENCY, VASOCONSTRICTION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828368-B2 | Therapeutic treatments using centhaquin | ADRA2A, ADRB3, HSPH1 | GNRHR 3929/4885EDNRB 502/4885KMT2A 2627/4885 |
| US-20080260634-A1 | Diagnostic Use of Endothelin Etb Receptor Agonists and Eta Receptor Antagonists in Tumor Imaging | EDNRB, EDNRA, ECE1 | GNRHR 53/4885EDNRB 1/4885KMT2A 4182/4885 |
| US-20080207763-A1 | Method and Composition for Potentiating the Antipyretic Action of a Nonopiod Analgesic | COX15, PTGER3, PTGER4 | GNRHR 1937/4885EDNRB 8/4885KMT2A 4769/4885 |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | PSEN1, PSEN2, CHAT | GNRHR 1699/4885EDNRB 7/4885KMT2A 3240/4885 |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | GNRHR 3682/4885EDNRB 148/4885KMT2A 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.